XML 74 R34.htm IDEA: XBRL DOCUMENT v3.22.0.1
ASSET ACQUISITION (Details Narrative) - USD ($)
Nov. 09, 2021
Nov. 09, 2021
Nov. 30, 2021
Aug. 31, 2021
Aug. 31, 2020
Amount received $ 15,000,000 $ 15,000,000      
Intangible assets $ 178,000        
Useful life asset 21 years        
Amortization $ 8,476        
Cash consideration paid $ 39,500,000 $ 39,500,000      
Interest on royalty,percentage 8.00%        
Common stock value per share     $ 0.001 $ 0.001 $ 0.001
Common stock value     $ 20,020 $ 188 $ 187
Common stock shares issued 555,556 555,556 20,020,239 188,616 187,194
Debt discount $ 55,556        
Mioxal [Member]          
Useful life asset 24 years        
Amortization $ 3,385,409        
S T Bio Sciences Ltd [Member]          
Cash consideration paid $ 350,000 $ 350,000      
Common stock value per share $ 2.05 $ 2.05      
Common stock value $ 40,654,827 $ 40,654,827      
Common stock shares issued 19,831,623 19,831,623      
Debt discount $ 500,000 $ 55,556      
Common Stock fully diluted aggregate fair value $ 41,004,827 41,004,827      
Shares acquired 19,831,623        
S T Bio Sciences Ltd [Member] | Tranche One [Member]          
Amount received $ 4,000,000 4,000,000      
S T Bio Sciences Ltd [Member] | Tranche Two [Member]          
Amount received 5,000,000 5,000,000      
S T Bio Sciences Ltd [Member] | Tranche Three [Member] | September 10, 2024 [Member]          
Amount received 6,000,000 6,000,000      
Ingenius Biotech [Member]          
Current and long-term liabilities 39,500,000 39,500,000      
Ingenius Biotech [Member] | January 15, 2022 [Member]          
Asset acquisition first installment 1,500,000 1,500,000      
Asset acquisition thereafter 3,500,000 3,500,000      
Asset acquisition aggregate amount 24,500,000 24,500,000      
Additional liabilities assumed 423,000 423,000      
Ingenius Biotech [Member] | April 15, 2022 [Member]          
Asset acquisition second installment $ 1,500,000 $ 1,500,000